ErikAllenImelMD
Endocrinology • Indianapolis, INLipid Metabolism, Osteoporosis & Bone Metabolism Medicine, Parathyroid, Pediatric Endocrinology
Professor, Medicine and Pediatrics, Indiana University School of Medicine
Dr. Imel is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
550 University Blvd
Ste 2180
Indianapolis, IN 46202Phone+1 317-944-7718Fax+1 317-944-1289
Education & Training
Indiana University School of MedicineFellowship, Pediatric Endocrinology, 2003 - 2007
University of RochesterResidency, Internal Medicine/Pediatrics, 1999 - 2003
University of Cincinnati College of MedicineClass of 1999
Certifications & Licensure
IN State Medical License 2003 - 2025
NY State Medical License 2003 - 2005- American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
- American Board of Pediatrics Pediatric Endocrinology
Clinical Trials
- Study of KRN23 (Burosumab), a Recombinant Fully Human Monoclonal Antibody Against Fibroblast Growth Factor 23 (FGF23), in Pediatric Subjects With X-linked Hypophosphatemia (XLH) Start of enrollment: 2014 Jul 02
- Iron Therapy for Autosomal Dominant Hypophosphatemic Rickets: A Pilot Project. Start of enrollment: 2014 Aug 01
- CFTR Modulator Effects on Bone and Muscle in Adults With Cystic Fibrosis Start of enrollment: 2019 Dec 18
- Join now to see all
Publications & Presentations
PubMed
- 23 citationsGlobal guidance for the recognition, diagnosis, and management of tumor-induced osteomalacia.Suzanne M Jan de Beur, Salvatore Minisola, Wei-Bo Xia, Bo Abrahamsen, Jean-Jacques Body
Journal of Internal Medicine. 2023-03-01 - 202 citationsIron Modifies Plasma FGF23 Differently in Autosomal Dominant Hypophosphatemic Rickets and Healthy HumansErik A. Imel, Munro Peacock, Amie K. Gray, Leah R. Padgett, Siu L. Hui
The Journal of Clinical Endocrinology and Metabolism. 2011-08-31 - 108 citationsThe Lifelong Impact of X-Linked Hypophosphatemia: Results From a Burden of Disease Survey.Alison Skrinar, Melita Dvorak-Ewell, Ayla Evins, Carolyn M. Macica, Agnès Linglart
Journal of the Endocrine Society. 2019-07-01
Journal Articles
- A Randomized, Double‐Blind, Placebo‐Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti‐FGF23 Antibody, in Adults with X‐Linked Hypophosphatemia: W...Thomas Weber, Mary D Ruppe, Anthony A Portale, Erik A Imel, Thomas O Carpenter, Karl L Insogna, Farzana Perwad, Pisit Pitukcheewanont, Journal of Bone and Mineral Research
Press Mentions
Burosumab Effects Persist Long-Term for Children with Rare Form of RicketsSeptember 16th, 2020
Burosumab Improves Symptom Relief in Genetic RicketsJuly 5th, 2019
Clinical Trial Improves Treatment of Genetic RicketsMay 18th, 2019- Join now to see all
Grant Support
- FGF23 In Pediatric Phosphate Physiology And X-Linked Hypophosphatemic Rickets.National Institute Of Arthritis And Musculoskeletal And Skin Diseases2009–2011
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
